Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes
- PMID: 23307532
- PMCID: PMC3596428
- DOI: 10.1158/1055-9965.EPI-12-1217
Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes
Abstract
Background: Our genome-wide association study (GWAS) of chronic lymphocytic leukemia (CLL) identified 4 highly correlated intronic variants within the IRF8 gene that were associated with CLL. These results were further supported by a recent meta-analysis of our GWAS with two other GWAS of CLL, supporting the IRF8 gene as a strong candidate for CLL risk.
Methods: To refine the genetic association of CLL risk, we conducted Sanger sequencing of IRF8 in 94 CLL cases and 96 controls. We then conducted fine mapping by genotyping 39 variants (of which 10 were identified from sequencing) in 745 CLL cases and 1,521 controls. We also assessed these associations with risk of other non-Hodgkin lymphoma (NHL) subtypes.
Results: The strongest association with CLL risk was observed with a common single-nucleotide polymorphism (SNP) located within the 3' untranslated region (UTR) of IRF8 (rs1044873, log additive OR = 0.7, P = 1.81 × 10(-6)). This SNP was not associated with the other NHL subtypes (all P > 0.05).
Conclusions: We provide evidence that rs1044873 in the IRF8 gene accounts for the initial GWAS signal for CLL risk. This association appears to be unique to CLL with little support for association with other common NHL subtypes. Future work is needed to assess functional role of IRF8 in CLL etiology.
Impact: These data provide support that a functional variant within the 3'UTR of IRF8 may be driving the GWAS signal seen on 16q24.1 for CLL risk.
Conflict of interest statement
The authors declare no competing financial interests.
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10–29. [Comparative Study]. - PubMed
-
- Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990–4997. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA118444/CA/NCI NIH HHS/United States
- CA97274/CA/NCI NIH HHS/United States
- CA148690/CA/NCI NIH HHS/United States
- R01 CA148690/CA/NCI NIH HHS/United States
- CA92153/CA/NCI NIH HHS/United States
- K08 CA134919/CA/NCI NIH HHS/United States
- P50 CA097274/CA/NCI NIH HHS/United States
- U01 CA118444/CA/NCI NIH HHS/United States
- P30 CA015083/CA/NCI NIH HHS/United States
- R01 CA092153/CA/NCI NIH HHS/United States
- NIH CA134919/CA/NCI NIH HHS/United States
- R01 CA095241/CA/NCI NIH HHS/United States
- N01 CA015083/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical